Bloomington’s 2025 economic story is about adapting and rising to meet challenges. Flexibility, strategic investment and ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a ...

SOUTH SAN FRANCISCO, Calif., June 11, 2025 /PRNewswire/ -- Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Novo Nordisk to ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk’s share price fell on the news, trading 0.8% lower after being 4% higher earlier in the day. The shares are down 32% year-to-date and 59% from their all-time high.

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

Novo Nordisk’s semaglutide drug is in a class of drugs known as GLP-1 agonists, which simulate a hormone that would naturally be released during digestion. Its drug, marketed as Ozempic, was ...

Over the past six months, its once-ascendant stock value is down a grim 50 percent. While Novo Nordisk is getting thrashed, Eli Lilly shares shot up by 14 percent in light of the latest news.